Sadik Yesil, MD
Neurology · Andalusia, ALNPI 1760471817
Payments from drug & device makers
Across 305 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$490
- UCB, Inc.$469
- Novartis$327
- Lilly USA, LLC$321
- Sunovion Pharmaceuticals Inc.$310
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,584100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 64 | $1,001 |
| AbbVie(2 entities) | 28 | $490 |
| UCB, Inc. | 22 | $469 |
| Novartis | 17 | $327 |
| Lilly USA, LLC | 16 | $321 |
| Sunovion Pharmaceuticals Inc. | 22 | $310 |
| Teva Pharmaceuticals USA, Inc. | 8 | $229 |
| Amneal Pharmaceuticals LLC | 9 | $210 |
| Otsuka America Pharmaceutical, Inc. | 10 | $193 |
| EMD Serono, Inc. | 12 | $191 |
| Lundbeck LLC | 8 | $177 |
| Argenx US, Inc. | 8 | $173 |
| Supernus Pharmaceuticals, Inc. | 9 | $151 |
| Biogen | 6 | $124 |
| SK Life Science, Inc. | 7 | $122 |
| Avanir Pharmaceuticals, Inc. | 9 | $113 |
| AstraZeneca | 6 | $107 |
| Grifols USA, LLC | 4 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $97 |
| Scilex Pharmaceuticals Inc. | 4 | $77 |
| Boston Scientific | 2 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Genentech USA, Inc. | 4 | $60 |
| CSL Behring | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Abbott | 3 | $51 |
| Catalyst Pharmaceuticals, Inc. | 1 | $36 |
| Neurelis, Inc. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Adamas Pharmaceuticals, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$5,596 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $374,003 |
| Nurtec OdtRimegepant Sulfate | 203 | $306,914 |
| Kesimpta PenOfatumumab | 16 | $168,640 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 24 | $166,986 |
| BetaseronInterferon Beta-1b | 14 | $133,182 |
| VumerityDiroximel Fumarate | 13 | $113,603 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,732 |
| UbrelvyUbrogepant | 57 | $105,411 |
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 21 | $72,361 |
| FingolimodFingolimod Hcl | 15 | $71,146 |
| AptiomEslicarbazepine Acetate | 30 | $51,556 |
| RexultiBrexpiprazole | 24 | $32,744 |
| QuliptaAtogepant | 28 | $30,893 |
| Aimovig AutoinjectorErenumab-Aooe | 33 | $29,403 |
| EliquisApixaban | 26 | $29,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $100 | $374,00314 claims |
| PfizerNurtec Odt, Eliquis | $1,001 | $336,269229 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $490 | $154,718106 claims |
| BiogenVumerity | $124 | $113,60313 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $310 | $51,55630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $193 | $32,74424 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $151 | $8,29913 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $210 | $2,55752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.
Other neurology in Andalusia
- Emily RiserBirmingham$7.1M
- Christopher LagankeCullman$5.9M
- Louis NaborsBirmingham$3.2M
- Belinda Savage-EdwardsHuntsville$2.8M
- Khurram BashirBirmingham$2.8M
- David GeldmacherBirmingham$2.6M
- Victor SungBirmingham$2M
- Mina LobbousBirmingham$1.8M
- Diane CounceBirmingham$1.4M
- Judy WhiteFlorala$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.